Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 174

1.

In-vitro viral suppressive capacity correlates with immune checkpoint marker expression on peripheral CD8+ T cells in treated HIV-positive patients.

Pannus P, Adams P, Willems E, Heyndrickx L, Florence E, Rutsaert S, De Spiegelaere W, Vandekerckhove L, Seguin-Devaux C, Vanham G.

AIDS. 2019 Mar 1;33(3):387-398. doi: 10.1097/QAD.0000000000002068.

PMID:
30702513
2.

Phase I clinical trial of an intranodally administered mRNA-based therapeutic vaccine against HIV-1 infection.

Leal L, Guardo AC, Morón-López S, Salgado M, Mothe B, Heirman C, Pannus P, Vanham G, van den Ham HJ, Gruters R, Andeweg A, Van Meirvenne S, Pich J, Arnaiz JA, Gatell JM, Brander C, Thielemans K, Martínez-Picado J, Plana M, García F; iHIVARNA consortium.

AIDS. 2018 Nov 13;32(17):2533-2545. doi: 10.1097/QAD.0000000000002026.

3.

Immunomodulatory Therapy of Visceral Leishmaniasis in Human Immunodeficiency Virus-Coinfected Patients.

Adriaensen W, Dorlo TPC, Vanham G, Kestens L, Kaye PM, van Griensven J.

Front Immunol. 2018 Jan 12;8:1943. doi: 10.3389/fimmu.2017.01943. eCollection 2017. Review.

4.

A longitudinal analysis of the vaginal microbiota and vaginal immune mediators in women from sub-Saharan Africa.

Jespers V, Kyongo J, Joseph S, Hardy L, Cools P, Crucitti T, Mwaura M, Ndayisaba G, Delany-Moretlwe S, Buyze J, Vanham G, van de Wijgert JHHM.

Sci Rep. 2017 Sep 20;7(1):11974. doi: 10.1038/s41598-017-12198-6.

5.

Correction: Viral genetic variation accounts for a third of variability in HIV-1 set-point viral load in Europe.

Blanquart F, Wymant C, Cornelissen M, Gall A, Bakker M, Bezemer D, Hall M, Hillebregt M, Ong SH, Albert J, Bannert N, Fellay J, Fransen K, Gourlay AJ, Grabowski MK, Gunsenheimer-Bartmeyer B, Günthard HF, Kivelä P, Kouyos R, Laeyendecker O, Liitsola K, Meyer L, Porter K, Ristola M, van Sighem A, Vanham G, Berkhout B, Kellam P, Reiss P, Fraser C; BEEHIVE collaboration.

PLoS Biol. 2017 Jul 13;15(7):e1002608. doi: 10.1371/journal.pbio.1002608. eCollection 2017 Jul.

6.

Viral genetic variation accounts for a third of variability in HIV-1 set-point viral load in Europe.

Blanquart F, Wymant C, Cornelissen M, Gall A, Bakker M, Bezemer D, Hall M, Hillebregt M, Ong SH, Albert J, Bannert N, Fellay J, Fransen K, Gourlay AJ, Grabowski MK, Gunsenheimer-Bartmeyer B, Günthard HF, Kivelä P, Kouyos R, Laeyendecker O, Liitsola K, Meyer L, Porter K, Ristola M, van Sighem A, Vanham G, Berkhout B, Kellam P, Reiss P, Fraser C; BEEHIVE collaboration.

PLoS Biol. 2017 Jun 12;15(6):e2001855. doi: 10.1371/journal.pbio.2001855. eCollection 2017 Jun. Erratum in: PLoS Biol. 2017 Jul 13;15(7):e1002608.

7.

Visualization of X4- and R5-Tropic HIV-1 Viruses Expressing Fluorescent Proteins in Human Endometrial Cells: Application to Tropism Study.

Terrasse R, Memmi M, Palle S, Heyndrickx L, Vanham G, Pozzetto B, Bourlet T.

PLoS One. 2017 Jan 6;12(1):e0169453. doi: 10.1371/journal.pone.0169453. eCollection 2017.

8.

CD4-mimetic sulfopeptide conjugates display sub-nanomolar anti-HIV-1 activity and protect macaques against a SHIV162P3 vaginal challenge.

Ariën KK, Baleux F, Desjardins D, Porrot F, Coïc YM, Michiels J, Bouchemal K, Bonnaffé D, Bruel T, Schwartz O, Le Grand R, Vanham G, Dereuddre-Bosquet N, Lortat-Jacob H.

Sci Rep. 2016 Oct 10;6:34829. doi: 10.1038/srep34829.

9.

Evolutionary Dynamics and Complicated Genetic Transmission Network Patterns of HIV-1 CRF01_AE among MSM in Shanghai, China.

Li X, Xue Y, Lin Y, Gai J, Zhang L, Cheng H, Ning Z, Zhou L, Zhu K, Vanham G, Kang L, Wang Y, Zhuang M, Pan Q, Zhong P.

Sci Rep. 2016 Oct 4;6:34729. doi: 10.1038/srep34729.

10.

Type I Interferons Interfere with the Capacity of mRNA Lipoplex Vaccines to Elicit Cytolytic T Cell Responses.

De Beuckelaer A, Pollard C, Van Lint S, Roose K, Van Hoecke L, Naessens T, Udhayakumar VK, Smet M, Sanders N, Lienenklaus S, Saelens X, Weiss S, Vanham G, Grooten J, De Koker S.

Mol Ther. 2016 Nov;24(11):2012-2020. doi: 10.1038/mt.2016.161. Epub 2016 Aug 10.

11.

Inhibition of HIV Virus by Neutralizing Vhh Attached to Dual Functional Liposomes Encapsulating Dapivirine.

Wang SX, Michiels J, Ariën KK, New R, Vanham G, Roitt I.

Nanoscale Res Lett. 2016 Dec;11(1):350. doi: 10.1186/s11671-016-1558-7. Epub 2016 Jul 28.

12.

Development and in Vitro Evaluation of a Microbicide Gel Formulation for a Novel Non-Nucleoside Reverse Transcriptase Inhibitor Belonging to the N-Dihydroalkyloxybenzyloxopyrimidines (N-DABOs) Family.

Tintori C, Brai A, Dasso Lang MC, Deodato D, Greco AM, Bizzarri BM, Cascone L, Casian A, Zamperini C, Dreassi E, Crespan E, Maga G, Vanham G, Ceresola E, Canducci F, Ariën KK, Botta M.

J Med Chem. 2016 Mar 24;59(6):2747-59. doi: 10.1021/acs.jmedchem.5b01979. Epub 2016 Mar 8.

PMID:
26898379
13.

Resistance and cross-resistance profile of the diaryltriazine NNRTI and candidate microbicide UAMC01398.

Ariën KK, Venkatraj M, Michiels J, Joossens J, Vereecken K, Van der Veken P, Heeres J, De Winter H, Heyndrickx L, Augustyns K, Vanham G.

J Antimicrob Chemother. 2016 May;71(5):1159-68. doi: 10.1093/jac/dkv501. Epub 2016 Feb 4.

PMID:
26850721
14.

2,6-Di(arylamino)-3-fluoropyridine Derivatives as HIV Non-Nucleoside Reverse Transcriptase Inhibitors.

Sergeyev S, Yadav AK, Franck P, Michiels J, Lewi P, Heeres J, Vanham G, Ariën KK, Vande Velde CM, De Winter H, Maes BU.

J Med Chem. 2016 Mar 10;59(5):1854-68. doi: 10.1021/acs.jmedchem.5b01336. Epub 2016 Feb 8.

PMID:
26785139
15.

Cross-Sectional Analysis of Selected Genital Tract Immunological Markers and Molecular Vaginal Microbiota in Sub-Saharan African Women, with Relevance to HIV Risk and Prevention.

Kyongo JK, Crucitti T, Menten J, Hardy L, Cools P, Michiels J, Delany-Moretlwe S, Mwaura M, Ndayisaba G, Joseph S, Fichorova R, van de Wijgert J, Vanham G, Ariën KK, Jespers V.

Clin Vaccine Immunol. 2015 May;22(5):526-38. doi: 10.1128/CVI.00762-14. Epub 2015 Mar 11.

16.

From human immunodeficiency virus non-nucleoside reverse transcriptase inhibitors to potent and selective antitrypanosomal compounds.

Venkatraj M, Ariën KK, Heeres J, Joossens J, Dirié B, Lyssens S, Michiels J, Cos P, Lewi PJ, Vanham G, Maes L, Van der Veken P, Augustyns K.

Bioorg Med Chem. 2014 Oct 1;22(19):5241-8. doi: 10.1016/j.bmc.2014.08.005. Epub 2014 Aug 14.

PMID:
25199582
17.

Evidence that HIV-1 CRF01_AE is associated with low CD4+T cell count and CXCR4 co-receptor usage in recently infected young men who have sex with men (MSM) in Shanghai, China.

Li X, Xue Y, Zhou L, Lin Y, Yu X, Wang X, Zhen X, Zhang W, Ning Z, Yue Q, Fu J, Shen F, Gai J, Xu Y, Mao J, Gao X, Shen X, Kang L, Vanham G, Cheng H, Wang Y, Zhuang M, Zhuang X, Pan Q, Zhong P.

PLoS One. 2014 Feb 21;9(2):e89462. doi: 10.1371/journal.pone.0089462. eCollection 2014. Erratum in: PLoS One. 2014;9(5):e97395.

18.

What is the significance of posttreatment control of HIV infection vis-à-vis functional cure?

Vanham G, Buvé A, Florence E, Seguin-Devaux C, Sáez-Cirión A.

AIDS. 2014 Feb 20;28(4):603-5. doi: 10.1097/QAD.0000000000000147. No abstract available.

19.

Development and in vitro evaluation of a vaginal microbicide gel formulation for UAMC01398, a novel diaryltriazine NNRTI against HIV-1.

Grammen C, Ariën KK, Venkatraj M, Joossens J, Van der Veken P, Heeres J, Lewi PJ, Haenen S, Augustyns K, Vanham G, Augustijns P, Brouwers J.

Antiviral Res. 2014 Jan;101:113-21. doi: 10.1016/j.antiviral.2013.11.005. Epub 2013 Nov 20.

PMID:
24269474
20.

Challenges and advances towards the rational design of mRNA vaccines.

Pollard C, De Koker S, Saelens X, Vanham G, Grooten J.

Trends Mol Med. 2013 Dec;19(12):705-13. doi: 10.1016/j.molmed.2013.09.002. Epub 2013 Oct 15. Review.

PMID:
24138818
21.

Selected HIV-1 Env trimeric formulations act as potent immunogens in a rabbit vaccination model.

Heyndrickx L, Stewart-Jones G, Jansson M, Schuitemaker H, Bowles E, Buonaguro L, Grevstad B, Vinner L, Vereecken K, Parker J, Ramaswamy M, Biswas P, Vanham G, Scarlatti G, Fomsgaard A; NGIN Consortium.

PLoS One. 2013 Sep 2;8(9):e74552. doi: 10.1371/journal.pone.0074552. eCollection 2013.

22.

The N276 glycosylation site is required for HIV-1 neutralization by the CD4 binding site specific HJ16 monoclonal antibody.

Balla-Jhagjhoorsingh SS, Corti D, Heyndrickx L, Willems E, Vereecken K, Davis D, Vanham G.

PLoS One. 2013 Jul 17;8(7):e68863. doi: 10.1371/journal.pone.0068863. Print 2013.

23.

Targeting of human antigen-presenting cell subsets.

Goyvaerts C, Dingemans J, De Groeve K, Heirman C, Van Gulck E, Vanham G, De Baetselier P, Thielemans K, Raes G, Breckpot K.

J Virol. 2013 Oct;87(20):11304-8. doi: 10.1128/JVI.01498-13. Epub 2013 Jul 17.

24.

Characterization of humoral responses to soluble trimeric HIV gp140 from a clade A Ugandan field isolate.

Visciano ML, Tagliamonte M, Stewart-Jones G, Heyndrickx L, Vanham G, Jansson M, Fomsgaard A, Grevstad B, Ramaswamy M, Buonaguro FM, Tornesello ML, Biswas P, Scarlatti G, Buonaguro L; NGIN Consortium.

J Transl Med. 2013 Jul 8;11:165. doi: 10.1186/1479-5876-11-165.

25.

In vitro and ex vivo evaluation of polymeric nanoparticles for vaginal and rectal delivery of the anti-HIV drug dapivirine.

das Neves J, Araújo F, Andrade F, Michiels J, Ariën KK, Vanham G, Amiji M, Bahia MF, Sarmento B.

Mol Pharm. 2013 Jul 1;10(7):2793-807. doi: 10.1021/mp4002365. Epub 2013 Jun 17.

PMID:
23738946
26.

Interfacial cavity filling to optimize CD4-mimetic miniprotein interactions with HIV-1 surface glycoprotein.

Morellato-Castillo L, Acharya P, Combes O, Michiels J, Descours A, Ramos OH, Yang Y, Vanham G, Ariën KK, Kwong PD, Martin L, Kessler P.

J Med Chem. 2013 Jun 27;56(12):5033-47. doi: 10.1021/jm4002988. Epub 2013 Jun 11.

27.

Diaryltriazine non-nucleoside reverse transcriptase inhibitors are potent candidates for pre-exposure prophylaxis in the prevention of sexual HIV transmission.

Ariën KK, Venkatraj M, Michiels J, Joossens J, Vereecken K, Van der Veken P, Abdellati S, Cuylaerts V, Crucitti T, Heyndrickx L, Heeres J, Augustyns K, Lewi PJ, Vanham G.

J Antimicrob Chemother. 2013 Sep;68(9):2038-47. doi: 10.1093/jac/dkt166. Epub 2013 May 3.

PMID:
23645585
28.

M48U1 CD4 mimetic has a sustained inhibitory effect on cell-associated HIV-1 by attenuating virion infectivity through gp120 shedding.

Selhorst P, Grupping K, Tong T, Crooks ET, Martin L, Vanham G, Binley JM, Ariën KK.

Retrovirology. 2013 Feb 1;10:12. doi: 10.1186/1742-4690-10-12.

29.

MiniCD4 microbicide prevents HIV infection of human mucosal explants and vaginal transmission of SHIV(162P3) in cynomolgus macaques.

Dereuddre-Bosquet N, Morellato-Castillo L, Brouwers J, Augustijns P, Bouchemal K, Ponchel G, Ramos OH, Herrera C, Stefanidou M, Shattock R, Heyndrickx L, Vanham G, Kessler P, Le Grand R, Martin L.

PLoS Pathog. 2012;8(12):e1003071. doi: 10.1371/journal.ppat.1003071. Epub 2012 Dec 6.

30.

Synthesis, evaluation and structure-activity relationships of triazine dimers as novel antiviral agents.

Venkatraj M, Ariën KK, Heeres J, Joossens J, Messagie J, Michiels J, Van der Veken P, Vanham G, Lewi PJ, Augustyns K.

Bioorg Med Chem Lett. 2012 Dec 1;22(23):7174-8. doi: 10.1016/j.bmcl.2012.09.066. Epub 2012 Sep 27.

PMID:
23084903
31.

Type I IFN counteracts the induction of antigen-specific immune responses by lipid-based delivery of mRNA vaccines.

Pollard C, Rejman J, De Haes W, Verrier B, Van Gulck E, Naessens T, De Smedt S, Bogaert P, Grooten J, Vanham G, De Koker S.

Mol Ther. 2013 Jan;21(1):251-9. doi: 10.1038/mt.2012.202. Epub 2012 Sep 25.

32.

Can immunotherapy be useful as a "functional cure" for infection with Human Immunodeficiency Virus-1?

Vanham G, Van Gulck E.

Retrovirology. 2012 Sep 7;9:72. doi: 10.1186/1742-4690-9-72. Review.

33.

Searching for lower female genital tract soluble and cellular biomarkers: defining levels and predictors in a cohort of healthy Caucasian women.

Kyongo JK, Jespers V, Goovaerts O, Michiels J, Menten J, Fichorova RN, Crucitti T, Vanham G, Ariën KK.

PLoS One. 2012;7(8):e43951. doi: 10.1371/journal.pone.0043951. Epub 2012 Aug 31.

34.

Internalization of mRNA lipoplexes by dendritic cells.

De Haes W, Van Mol G, Merlin C, De Smedt SC, Vanham G, Rejman J.

Mol Pharm. 2012 Oct 1;9(10):2942-9. Epub 2012 Aug 28.

PMID:
22894540
35.

Lipoplexes carrying mRNA encoding Gag protein modulate dendritic cells to stimulate HIV-specific immune responses.

De Haes W, Rejman J, Pollard C, Merlin C, Vekemans M, Florence E, De Smedt SC, Grooten J, Vanham G, De Koker S, Van Gulck E.

Nanomedicine (Lond). 2013 Jan;8(1):77-87. doi: 10.2217/nnm.12.97. Epub 2012 Aug 14.

PMID:
22891862
36.

Interleukin-12p70 expression by dendritic cells of HIV-1-infected patients fails to stimulate gag-specific immune responses.

Van Gulck E, Cools N, Atkinson D, Bracke L, Vereecken K, Vekemans M, Van Tendeloo VF, Berneman ZN, Vanham G.

Clin Dev Immunol. 2012;2012:184979. doi: 10.1155/2012/184979. Epub 2012 Jul 12.

37.

An improved protocol for efficient engraftment in NOD/LTSZ-SCIDIL-2Rγnull mice allows HIV replication and development of anti-HIV immune responses.

Singh M, Singh P, Gaudray G, Musumeci L, Thielen C, Vaira D, Vandergeeten C, Delacroix L, Van Gulck E, Vanham G, de Leval L, Rahmouni S, Moutschen M.

PLoS One. 2012;7(6):e38491. doi: 10.1371/journal.pone.0038491. Epub 2012 Jun 4.

38.

Immune and viral correlates of "secondary viral control" after treatment interruption in chronically HIV-1 infected patients.

Van Gulck E, Bracke L, Heyndrickx L, Coppens S, Atkinson D, Merlin C, Pasternak A, Florence E, Vanham G.

PLoS One. 2012;7(5):e37792. doi: 10.1371/journal.pone.0037792. Epub 2012 May 30.

39.

CD34-derived dendritic cells transfected ex vivo with HIV-Gag mRNA induce polyfunctional T-cell responses in nonhuman primates.

Romain G, van Gulck E, Epaulard O, Oh S, Li D, Zurawski G, Zurawski S, Cosma A, Adam L, Chapon C, Todorova B, Banchereau J, Dereuddre-Bosquet N, Vanham G, Le Grand R, Martinon F.

Eur J Immunol. 2012 Aug;42(8):2019-30. doi: 10.1002/eji.201242478. Epub 2012 Jul 4.

40.

MiniCD4 protein resistance mutations affect binding to the HIV-1 gp120 CD4 binding site and decrease entry efficiency.

Grupping K, Selhorst P, Michiels J, Vereecken K, Heyndrickx L, Kessler P, Vanham G, Martin L, Ariën KK.

Retrovirology. 2012 May 2;9:36. doi: 10.1186/1742-4690-9-36.

41.

Identification of a highly conserved valine-glycine-phenylalanine amino acid triplet required for HIV-1 Nef function.

Meuwissen PJ, Stolp B, Iannucci V, Vermeire J, Naessens E, Saksela K, Geyer M, Vanham G, Arien KK, Fackler OT, Verhasselt B.

Retrovirology. 2012 Apr 27;9:34. doi: 10.1186/1742-4690-9-34.

42.

Monocytes contribute to differential immune pressure on R5 versus X4 HIV through the adipocytokine visfatin/NAMPT.

Van den Bergh R, Morin S, Sass HJ, Grzesiek S, Vekemans M, Florence E, Tran HT, Imiru RG, Heyndrickx L, Vanham G, De Baetselier P, Raes G.

PLoS One. 2012;7(4):e35074. doi: 10.1371/journal.pone.0035074. Epub 2012 Apr 6.

43.

Ex vivo models of HIV sexual transmission and microbicide development.

Ariën KK, Kyongo JK, Vanham G.

Curr HIV Res. 2012 Jan 1;10(1):73-8. Review.

PMID:
22264048
44.

Reverse transcriptase inhibitors as microbicides.

Lewi P, Heeres J, Ariën K, Venkatraj M, Joossens J, Van der Veken P, Augustyns K, Vanham G.

Curr HIV Res. 2012 Jan 1;10(1):27-35. Review.

PMID:
22264043
45.

HIV microbicides: where are we now?

Quiñones-Mateu ME, Vanham G.

Curr HIV Res. 2012 Jan 1;10(1):1-2.

PMID:
22264039
46.

Possible implication of NFKB1A and NKG2D genes in susceptibility to HTLV-1-associated myelopathy/tropical spastic paraparesis in Peruvian patients infected with HTLV-1.

Talledo M, López G, Huyghe JR, Verdonck K, González E, Clark D, Vanham G, Gotuzzo E, Van Camp G, Van Laer L.

J Med Virol. 2012 Feb;84(2):319-26. doi: 10.1002/jmv.22255.

PMID:
22170554
47.

DC-SIGN increases the affinity of HIV-1 envelope glycoprotein interaction with CD4.

Hijazi K, Wang Y, Scala C, Jeffs S, Longstaff C, Stieh D, Haggarty B, Vanham G, Schols D, Balzarini J, Jones IM, Hoxie J, Shattock R, Kelly CG.

PLoS One. 2011;6(12):e28307. doi: 10.1371/journal.pone.0028307. Epub 2011 Dec 7.

48.

mRNA-based dendritic cell vaccination induces potent antiviral T-cell responses in HIV-1-infected patients.

Van Gulck E, Vlieghe E, Vekemans M, Van Tendeloo VF, Van De Velde A, Smits E, Anguille S, Cools N, Goossens H, Mertens L, De Haes W, Wong J, Florence E, Vanham G, Berneman ZN.

AIDS. 2012 Feb 20;26(4):F1-12. doi: 10.1097/QAD.0b013e32834f33e8.

PMID:
22156965
49.

In vitro activities of candidate microbicides against cell-associated HIV.

Selhorst P, Grupping K, Bourlet T, Delézay O, Ariën KK, Vanham G.

Antimicrob Agents Chemother. 2012 Feb;56(2):805-15. doi: 10.1128/AAC.05801-11. Epub 2011 Nov 14.

50.

Polymeric nanoparticles affect the intracellular delivery, antiretroviral activity and cytotoxicity of the microbicide drug candidate dapivirine.

das Neves J, Michiels J, Ariën KK, Vanham G, Amiji M, Bahia MF, Sarmento B.

Pharm Res. 2012 Jun;29(6):1468-84. doi: 10.1007/s11095-011-0622-3. Epub 2011 Nov 10.

PMID:
22072053

Supplemental Content

Loading ...
Support Center